The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
The company will be the first to take a FcRH5-targeting project into phase 3.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.